Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

5 Years' Follow-up Assessment of Surgical Repair for ACL Proximal Rupture

NCT06178497 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2023-12-01
Last updated
2026-08-20

Condition(s) studied

ACL - Anterior Cruciate Ligament Deficiency

Study summary

Isolated ruptures of ACL (anterior cruciate ligament) are ligament injuries that can be proximal, central or distal. Treatment of patients with proximal lesions should be graded. Functional treatment can be reserved for low-demanding patients in whom the practice level is limited and progression risk to a functionally unstable knee less marked. In athletes, the risk of a new sprain must be explained and the patient will choose functional treatment or surgical treatment.

Surgical treatment generally involves ligamentoplasty at the expense of a knee tendon to replace the ruptured ACL. In the context of proximal ACL rupture, the patient can be offered surgical repair of the ACL. There are numerous studies on ACL ligamentoplasties results but literature is poor on modern ACL repair outcomes.

In this context, this study aims to describe the relapse rate at 5 years of patients operated for a proximal ACL tear.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient, male or female, aged ≥ 18 years * Patient with no history of knee surgery except meniscal surgery * Patient with an isolated proximal Sherman 1 or 2 ACL tear * Patient with a proximal Sherman 1 or 2 ACL tear associated to a meniscal lesion * Patient with a proximal ACL tear associated with an injury to the MCL or LCL grade 1 or 2 but not grade 3 * Patient whose period is less than 3 months between the date of the accident and the surgery * Patient who received surgical repair between January 2019 and July 2021 Exclusion Criteria: * Patient with contralateral ACL tear * Patient with ACL tear Sherman 3 or 4 * Patient with a surgical history on the knee concerned, other than meniscal surgery

Primary outcome measure(s)

  • ACL rupture relapse rate — 1 day
    ACL rupture relapse will be assessed on MRI 5 years after ACL surgery

Trial sites (1)

FacilityCityRegionStatus
Hôpital Privé La Louvière Lille Choisir Une Région Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06178497 on ClinicalTrials.gov ↗ ← All trials in France